EE04453B1 - Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena - Google Patents

Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Info

Publication number
EE04453B1
EE04453B1 EE9700255A EE9700255A EE04453B1 EE 04453 B1 EE04453 B1 EE 04453B1 EE 9700255 A EE9700255 A EE 9700255A EE 9700255 A EE9700255 A EE 9700255A EE 04453 B1 EE04453 B1 EE 04453B1
Authority
EE
Estonia
Prior art keywords
beta
activating agent
lymphotoxin
lhc
carrier
Prior art date
Application number
EE9700255A
Other languages
English (en)
Estonian (et)
Other versions
EE9700255A (et
Inventor
L. Browning Jeffrey
Meier Werner
D. Benjamin Christopher
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9700255A publication Critical patent/EE9700255A/xx
Publication of EE04453B1 publication Critical patent/EE04453B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EE9700255A 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena EE04453B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (2)

Publication Number Publication Date
EE9700255A EE9700255A (et) 1998-04-15
EE04453B1 true EE04453B1 (et) 2005-04-15

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700255A EE04453B1 (et) 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Country Status (24)

Country Link
EP (2) EP0809510B1 (zh)
JP (2) JPH10513161A (zh)
KR (2) KR100470739B1 (zh)
CN (3) CN1900116A (zh)
AT (1) ATE268604T1 (zh)
AU (1) AU725351B2 (zh)
BG (1) BG62599B1 (zh)
BR (1) BR9606808A (zh)
CA (1) CA2211443A1 (zh)
CZ (1) CZ298711B6 (zh)
DE (1) DE69632681T2 (zh)
DK (1) DK0809510T3 (zh)
EA (1) EA000096B1 (zh)
EE (1) EE04453B1 (zh)
ES (1) ES2220972T3 (zh)
FI (1) FI119359B (zh)
HU (1) HUP9801746A3 (zh)
NO (1) NO322744B1 (zh)
NZ (1) NZ303405A (zh)
PL (1) PL185364B1 (zh)
PT (1) PT809510E (zh)
RO (1) RO118634B1 (zh)
SK (1) SK286497B6 (zh)
WO (1) WO1996022788A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CA2344049C (en) 1998-10-09 2009-12-15 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
MXPA03003144A (es) 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
AU2009298708A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
CN104244718A (zh) * 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 抗体-药物缀合物以及相关化合物、组合物和方法
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
WO1992000329A1 (en) * 1990-06-27 1992-01-09 Biogen, Inc. Surface complexed lymphotoxin
DE69334224D1 (de) * 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon

Also Published As

Publication number Publication date
EA199700144A1 (ru) 1997-12-30
FI119359B (fi) 2008-10-31
CN1177302A (zh) 1998-03-25
ES2220972T3 (es) 2004-12-16
EA000096B1 (ru) 1998-08-27
EP0809510A1 (en) 1997-12-03
CN1900116A (zh) 2007-01-24
CN1146442C (zh) 2004-04-21
FI973118A0 (fi) 1997-07-25
DK0809510T3 (da) 2004-10-04
JP2007169296A (ja) 2007-07-05
KR100475492B1 (ko) 2005-03-14
PL321758A1 (en) 1997-12-22
DE69632681D1 (de) 2004-07-15
NO973385D0 (no) 1997-07-22
RO118634B1 (ro) 2003-08-29
EP1407781A1 (en) 2004-04-14
WO1996022788A1 (en) 1996-08-01
FI973118A7 (fi) 1997-09-25
PL185364B1 (pl) 2003-04-30
CN1589902A (zh) 2005-03-09
JPH10513161A (ja) 1998-12-15
EP0809510B1 (en) 2004-06-09
NZ303405A (en) 2000-02-28
BG62599B1 (bg) 2000-03-31
BG101855A (en) 1998-04-30
CA2211443A1 (en) 1996-08-01
HUP9801746A2 (hu) 1998-11-30
BR9606808A (pt) 1997-12-30
KR20040102364A (ko) 2004-12-04
HUP9801746A3 (en) 2000-11-28
CZ298711B6 (cs) 2008-01-02
ATE268604T1 (de) 2004-06-15
AU4970496A (en) 1996-08-14
NO322744B1 (no) 2006-12-04
EE9700255A (et) 1998-04-15
SK286497B6 (sk) 2008-11-06
PT809510E (pt) 2004-09-30
CZ236197A3 (cs) 1998-02-18
HK1006356A1 (zh) 1999-02-26
KR19980701816A (ko) 1998-06-25
KR100470739B1 (ko) 2005-09-02
MX9705629A (es) 1997-10-31
AU725351B2 (en) 2000-10-12
NO973385L (no) 1997-09-25
DE69632681T2 (de) 2005-06-09
SK98697A3 (en) 2000-02-14

Similar Documents

Publication Publication Date Title
EE04453B1 (et) Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena
Smith et al. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid
AU2332188A (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
YU83600A (sh) Adenozin a3 receptorski modulatori
NO961706L (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
IL180924A (en) Method for regulating cell proliferation and cell death
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
Gonzalez et al. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells
DE69705312D1 (de) N6-heterocyclisch-substituierte adenosin-derivate
AU3897999A (en) Multi-analyte diagnostic system and computer implemented process for same
AU5671096A (en) Methods, nucleotide sequences and host cells for assaying ex ogenous and endogenous protease activity
WO1999016888A3 (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
AU5465694A (en) Determination of peptide motifs on mhc molecules
AR021353A1 (es) Proceso para el procesamiento de sacarosa en glucosa.
WO1991011201A3 (en) Compounds
EP1144666A3 (en) Replication deficient baculovirus expression system
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
Friedman Can O 6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?
De Bellis et al. In vitro studies of histone glycation
Maassen et al. Comparison by photoaffinity labeling of the proteins involved in GTP hydrolysis from 70S ribosomes and a 5S RNA-protein complex from bacillus stearothermophilus
WO1996012508A3 (en) Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung

Legal Events

Date Code Title Description
HK1A Erratum in gazette
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100126